

房地產租售
Sale/Rent

***糖城雅房出租**
分租亦可,治安良好
環境優雅,重新裝潢
新地磚,好區,5分鐘到
59號,6號高速公路,
5房2衛,最優Clement
高中,初中,意者請電:
832-287-8233

***新買 House**
雅房出租
只限女性,不抽煙,
包水電,
每月租金500.
聯系電話:
832-948-4668

休士頓民宿租 Houston Hostel USA
中國城惠康前,百利大道上,獨立屋,旅館式
套房,(房內附-書桌,餐桌,Cable電視及冰箱),
無限快速上網,包水電,拎包入住,免簽長約,
月租最少1個月起,16年來感謝舊客戶推薦
Line/微信: **houstontours**
電/簡訊: **832-640-3888** Ruby 陳碧如

ITC 多間高雅辦公室租
環境高雅, 安全, 安靜,
包水電, 免費高速光纖上網, 辦公傢具,
近中國城5分鐘. 有大停車場. 多間辦公室出租, \$500
281-498-4310 Lisa (中文)
281-983-8152 Jennifer (英文)

Real Estate
房地產租售

極佳 Condo 售
Mid High Rise 極佳房,
1房/1全衛浴, 870呎
內有洗衣干衣機, 瓷磚/
木地板, 全花崗石枱面,
5分鐘到中國城.
僅售 8萬7千
意者請電: 非誠勿擾
281-690-8080

房地產租售
Sale/Rent

福地出售
Westheimer/Dairy Ashford
黃金地段福地
高地基,可豎碑,以上
含永久地契,永久護理
低於市價,投資機會
意者請電:
626-675-6663

International Trade Center
Office for Rent

●每格可容中文大字(標題)6字及小字(內容)50字,
英文字母及數字二字為中文小字一字, 空格標點符號均需計算。
※English title: 12 letter ※English content: 120 letters
●廣告內容均由委刊者提供, 本報一概不負責任。
●廣告涉有爭議, 本報保留拒絕刊登及修改廣告或暫停刊登之權利。
●涉及法律責任廣告, 需提供身份證件及當事人簽字負責, 本報概不負責。
●廣告刊出如有錯誤, 請於二日內前來更正, 如係本報排版錯誤, 將予以免費補刊, 但以二天為限。
●分類廣告請預付廣告費, 如中途停刊者, 恕不退還費用。
●刊登一個月以下者, 廣告均不得改稿, 若需改稿每次酌收費用5元
●本報接受 VISA 及 MASTER 信用卡付費, 如電話(Tel)或傳真(Fax)
訂稿委刊, 請告知信用卡號碼/姓名/有效期限/ CVV 號/ZIP code
Address 號, 其訂稿如有錯誤由客戶自行負責, 恕不補登。
●截稿時間: 星期一至五 2:30pm, 平時/周六日請微信: **AD7133021553**
截稿或之前訂稿, 立即上網, 其稿將在第二天刊登報紙。

看 護 服 務
200
Health Care Service

***誠徵老人照顧家庭看護**
全職或半工,男女不拘皆可,
須報稅,地點在糖城和休士頓地區.
電話: **713-271-8515**(公司)
或: **713-820-5748**(私人)

家政助理
Housekeeper

***誠聘家務助理**
家住1-10/8號
煮飯及做家務
一周工作3-5天
會國語/粵語或英語
時間彈性:
約下午3-9點
917-566-2211

***Katy 高薪**
誠聘 全職阿姨,
做飯、做家務,
開車接孩子上下學!
孩子已大!
住家不住家均可!
電: **832-546-7746**

分類廣告價目表 CLASSIFIED AD. RATE				
週數 Week	一 週	二 週	三 週	一 月
格數 Size	1 wk	2 wks	3 wks	1 mon
1 格 (1 box)	\$45	\$80	\$105	\$125
2 格 (2boxes)	\$90	\$160	\$210	\$250
3 格 (3boxes)	\$135	\$240	\$315	\$375
4 格 (4boxes)	\$180	\$320	\$420	\$500
6 格 (6boxes)	\$270	\$480	\$630	\$750
EFFECTIVE: 從2009年11月1日起實施				

聘請住家阿姨
位 Memorial, 每周5天,
基本英文溝通,
簡單打掃, 洗衣服,
會煮江浙菜, 作息有規
律高標準要求的阿姨,
薪水\$4000+
最好上海人. 請電:
832-908-0878

Katy 聘請管家
做飯, 做家務;
需打好新冠疫苗,
說普通話; 能開車。
薪優, 詳情請電:
713-927-4283

Home Service

***誠聘阿姨**
協助照料孩子(父母都在家上班), 做簡單家務,
周一到四上午8-10點,
周五8-3點, 15小時/周
愛乾淨, 誠實負責, 坐標
77007. \$15-\$20/小時
有意請聯系微信:
jingang749814

***聘請通勤阿姨**
3口之家, 4個月女寶,
說簡單英文.
一周工作5天,
8am-5pm, \$20/小時,
地址: Houston,
near Greenway Plaza
請短信:
502-833-8808

月嫂/保姆
家住聖安東尼奧
(San Antonio)
誠請 月嫂(陪月).
一個月後轉為保姆.
住家通勤均可, 薪優.
意者請電:
210-863-3888
213-631-8631

300
Company Hiring
公司請人

分類廣告專頁

***裝修請人**
誠 請
裝修師傅及小工
會英語為佳
有意者請電:
346-383-1057

Food Distributor
A/R, Offices Assistant
Salesperson &
Warehouse Loading
speaking Chinese & simple
English. Lily & Helen
713-383-8818
or Email: **helen@fourseasonsfood.com**

***食品公司誠徵**
工廠生產線
全工操作員數名
有身份, 有經驗優先.
意者請電:
281-908-6800

中國城黃金廣場
方太專門店, 薪優,
誠聘男女員工
有意者請電:
713-772-7888
713-772-2889

保險公司請人
誠請會計和管理.
勤奮好學, 三年工作
經驗以上, 待遇良好.
工作環境好, 可辦綠卡
請來電或短訊:
832-868-1090

誠徵醫務助理
近中國城
免費培訓
履歷請送:
Julie@hbctx.com

安防公司誠聘
●辦公室文員:
英文流利, 認真負責,
近中國城, 薪優。
●安裝技術人員:
簡單英文, 公司培訓,
有木工, 鉗工經驗優先,
年薪(5-8萬), 請電
346-970-7928

貿易公司誠聘
上門產品檢測一名
需有駕照和車, 性
別經驗不限,
能英語交流
有意者請電或短信:
281-650-6136

公司聘請
辦公室財務人員,
Bookkeeping.
有一年的簿記經驗,
中英文流利。電話:
281-782-3280
Email: **hrwant36@gmail.com**

刊登廣告
微信連絡
AD7133021553

美南新聞招聘視頻剪輯
美南新聞集團招聘剪輯, 需要會使用剪
輯軟件和導播機器, 參與現場錄制。
一經錄用, 待遇從優。
有意者請發郵件給: Jessie 聯系
Jessiew@scdaily.com

***Accountant/CPA**
-CPA firm in S.W. HOUSTON, TX
1 to 5 years CPA firm experiences in tax
or audit. Experiences in QuickBooks,
Lacerte, CCH preferred. Bilingual English/
Chinese preferred. Also need bookkeeper.
Will train, experience in QB preferred.
Resume email to: **email@cmcdllc.com**

***Sugar Land Company**
has immediate opening for
full time accounting position.
Experience preferred.
Please send resume to
carolzhang531@yahoo.com
or contact at: **832-335-0150**

Experience Accountant
2-year related working experience
Bachelor Degree in accounting
Fluent in English and Spanish
carrie.chiang73@gmail.com
6969 N. Freeway, Houston, TX

Office Assistant
Fluent in English, Spanish and Chinese
Highly motivated / Organized
Excellent knowledge of MS Excel
carrie.chiang73@gmail.com
6969 N. Freeway, Houston, TX

公司請人
誠聘機械維修工一名
需有機械及電器基礎。
~~薪金面議~~
聯系請電 Kent : **713-819-1633**

建築工程公司誠聘
工程項目助理
需有駕照和車, 能英文交流。
需有責任心及良好的溝通
和解決問題的能力。
意者請電: **832-289-2279**

***GMCC 萬通貸款**
高速成長, Direct Lender.
直接中核 (高達五百萬) 直接放款, 誠招
有經驗的高效率的 **Loan Processor**
工作地點在 Houston.
多成長機會, 待遇優厚 Full benefits
(health insurance , 401k match)
Email resume : **info@gmccloan.com**

保險代理公司 請人
誠徵 全工或半工助理:
有經驗及執照者有 bonus,
沒經驗者可培訓。需中英文流利。
意者請電郵簡歷及薪資要求及歷史到:
jericlul@luins.com
或短信到: **832-876-8399**

公寓誠聘
有經驗空調, 水電維修人員一名,
薪金面議, 若試用期通過, 可享有薪假
期和申請住宿, 醫保, 401K 福利。
聯絡電話: **713-777-0212**
M-F 9:00AM-6:00PM

We are Signs 招牌公司招聘
●建築焊工-需有經驗
●鉗工-需有經驗
●組裝工-無經驗可, 男女不拘(女性優先)
●設計師
意者請電: **832-266-2637**
履歷至: **wearesignsusa@gmail.com**

公司誠徵
●倉管人員: 可搬動50磅。
●辦公室文員: 需英文流利。
●安裝助手: 懂水電優先, 可培訓。
有工卡。薪優。
發簡歷至: **pnp650@sbcglobal.net**
或電: **713-291-8225**

石油貿易公司招 Accountant
要求有會計工作經驗,
有貿易物流經驗者更佳, 中英文流利,
會熟練使用 Quickbook,
在美有工作許可, 薪優面談,
工作地點 Katy, TX. 簡歷發至郵箱:
alanz@hectomind.com

Experienced Industrial
***Sewers and Seamstresses**
Apply in person at :
9350 South Point Dr. Houston, Texas 77054
Monday-Thursdays 9 AM- 2 PM
Great Hours *Great Benefits
* Paid Time Off *Competitive Pay
Equal Opportunity Employer

健康保險公司, 誠聘辦公室職員
需有身份, 簡單讀寫英文。
態度積極, 願意學習。無經驗者歡迎。
高中以上學歷。
提供健康, 人壽和意外險, 年假和 401K
公司位於6號和10號附近
請電郵簡歷: **jhung@newerallife.com**
or 來電 Jenny **281-599-5810**

糖城食品進口批發公司招聘
全職財務和倉庫人員各1名。
薪優面議(電議)。周一至周五全職
財務能熟練使用 Quickbooks 者優先考慮
須會英文, 合法報稅,
有意者請電郵簡歷至:
sugarlandfood@gmail.com
或撥打電話: **832-868-8168**

美南新聞電子報

BANKCARD SERVICES
信用卡公司急聘業務代表
業務代表多名: 保障底薪+高獎金+高佣金+福利. 帶薪培訓
Bankcard Services now is hiring **Sales Reps**
Base Salary + Commission + Incentive + Bonus
Email : **Jason.kwon@ebankcardservice.com**
Ethan.jiang@ebankcardservice.com
810 Hwy 6 South Suite#113 Houston, TX 77079

Thunder Group Texas Warehouse Worker
Employment Type: **Full Time (40 + hour)**
Warehouse worker job summary
Perform an array of functions that may include receiving & processing
incoming stocking materials, picking and filling orders from stock,
packing and shipping orders, or managing, organizing & retrieving
stock in the warehouse Address: **10702 cash road, Stafford, TX 77477**
Call: **713-690-0111** or email to
brianc@thundergroup.com for interview appointment

急需! 急需!!
休士頓窗簾廠
急招有經驗裁縫女工
意者請洽:
832-878-5686

***An International Electronics company**
in Houston is currently seeking new talent to join our team.
Sr. Customer Service Representative/Logistics Specialist
●Bachelor's Degree or equivalent experience with business or
supply chain background
●1-2 years working experience
●ERP - SAP experiences are preferred
●Take full ownership of customer issues & show a strong
commitment to going above & beyond
●Manages logistics operations to ensure efficient and accurate
delivery of shipments
●Positive Attitude. Dependable. Takes initiative.
●Excellent communication skills (spoken & written).
●Bilingual (Mandarin & English) is preferable.
Please email your resume to
lwang@telcointercon.com Attn: HR

Gillman Honda Fort Bend
hiring for all positions
● Sales
● Automotive Technician
● Internet sales
● Service Advisors
● Finance manager
We are looking for people that are hardworking,
committed to excellence that will go the extra
mile for our customers.
Income potential up to 75,000 per year plus bonuses.
Health benefits, 401k benefits, 5 day work week.
Tel: **281-341-2277**
Email: **Ffontenot@teamgillman.com**
24875 Southwest Freeway, Rosenberg, TX 77471
www.HondaFortbend.com

EVA AIR A STAR ALLIANCE MEMBER	
International Airlines near HOU has immediate opening for full-time positions. Experience related to the position is preferred but entry-level is also welcomed. Please specify position and salary expectation on resume and email to HOUTOBR@evaair.com	
Branch Office	Job Openings
Houston	Passenger Inside Sales
	Cargo Reservation
Bilingual English/Chinese a plus, Good communication & customer services skills, Computer proficiency, Self-motivated. Benefits include zero employee contribution for group health & life insurance, free/discount air tickets, and matching 401(k). EOE-M/F/D/V	

婦科診所誠徵
一名 前檯/財務助理
一名 護理/醫生助理
Fluent in English/Chinese
Familiar with Computer/EMR
FT/PT, Competitive salary
Experienced/Entry level
text: **832-477-3649**
ch7515@gmail.com
聘請會計
需懂操作 Quickbook
有會計經驗,
懂 Excel, Word
能英文說寫, 工作認真
Email: **susan@impressionbridal.com**
請電: **281-804-2027**



If you would like to share news or information with our readers, please send the unique stories, business

news organization events, and school news to us including your name and phone number in case more information is needed.

For news and information consideration, please send to News@scdaily.com or contact
John Robbins 281-965-6390
Jun Gai 281-498-4310

Publisher: Wea H. Lee
President: Catherine Lee
Editor: John Robbins

Address: 11122 Bellaire Blvd., Houston, TX 77072
E-mail: News@scdaily.com



Inside C2

Southern DAILY

Make Today Different

Southern Daily News is published by Southern News Group Daily

Wednesday, November 24 2021|

Driver to face homicide charges for deaths at Wisconsin Christmas parade

WAUKESHA, Wis., Nov 22 (Reuters) - The man accused of deliberately driving his car into a crowded Milwaukee-area Christmas parade over the weekend, killing five people and injuring dozens of others, was suspected in an earlier domestic disturbance, police said on Monday.

The suspect, Darrell Brooks, 39, was arrested near the scene of Sunday's vehicular attack in Waukesha, Wisconsin, and faces five counts of first-degree homicide, Waukesha Police Chief Daniel Thompson said.
In addition to the five people killed - ranging in age from 52 to 81 - another 48 were injured, including six children who remained hospitalized in critical condition on Monday, authorities said.

Among the victims were members of a parade group calling themselves the "Dancing Grannies," according to a statement posted on Facebook on Monday.
Thompson said the motive for the attack was still a mystery but that it was clear the suspect had acted intentionally.

"He drove right through the barricades and the officers," Thompson told a briefing, adding the authorities had ruled out terrorism as a motive. Sue Oppen, the Waukesha County district attorney, said the suspect was believed to have acted alone.

Police were not pursuing Brooks when he plowed into the parade, but one officer fired shots to try to stop the sports utility vehicle, the police chief said.

"Minutes after the incident occurred, I responded to the scene," Thompson said. "And what I saw out of chaos and tragedy was heroes -- first responders in the community coming together and working together on triaging victims."

The FBI was assisting local police in their investigation.

Brooks has a criminal history and was recently released on \$1,000 bail, an amount the Milwaukee County District Attorney's Office called "inappropriately low in light of the nature of the recent charges" against him. Brooks was charged on Nov. 5 with obstructing an officer, battery, reckless endangerment, disorderly conduct and felony bail jumping.

Around the time of Sunday's carnage, police also had received a complaint of a domestic disturbance involving Brooks and a knife but were unable to respond because they were



Chairs are left abandoned on Main Street the morning after a car plowed through a holiday parade in Waukesha, Wisconsin, U.S., November 22, 2021. REUTERS/Cheney Orr

preoccupied with the parade, Thompson said.

"Was there an initial complaint of a knife being involved? Yes," he said. "Do we know if there actually was one there? We don't."

The chief said investigators had no information suggesting Brooks, a resident of Milwaukee, knew anyone in the parade.

A police officer walks in the street after a car plowed through a crowd at a holiday parade in Waukesha, Wisconsin, U.S., in this still image obtained from a November 21, 2021 social media video. Jordan Woynilko/Handout via REUTERS
Chairs are left abandoned on Main Street the morning after a car plowed through a holiday parade in Waukesha, Wisconsin, U.S., November 22, 2021. REUTERS/Cheney Orr
Darrell Brooks poses for a booking photograph at the Milwaukee County Jail in Milwaukee, Wisconsin, U.S. November 3, 2021. Milwaukee County Sheriff's Office/Handout via REUTERS
Chairs are left abandoned on Main Street the morning after a car plowed through a holiday parade in Waukesha, Wisconsin, U.S., November 22, 2021. REUTERS/Cheney Orr

'STILL TOTALLY SHOCKED'

Police identified the five dead as Virginia Sorenson, 79; LeAnna Owen, 71; Tamara

Durand, 52; Jane Kulich, 52; and Wilhelm Hospel, 81.

On the morning after Sunday's carnage, a pink hat, a lone shoe and candy lay strewn across the main thoroughfare in Waukesha.

Dozens of orange evidence circles were painted on the street and most shops were closed in the city's downtown district. A woman tied a bouquet of flowers to a street post as police officers blocked intersections along the main road.

"It was terrifying," Waukesha resident Brian Hoffman, 33, who was present as the vehicle rammed through parade attendees, recalled as he sat on a stoop near the scene on Monday. "I saw children who were run over. ... I am still totally shocked."

Video of the incident posted on social media showed a red SUV racing alongside the parade route and then into the procession, appearing to run over more than a dozen people before bystanders ran from sidewalks to help.

The Children's Wisconsin hospital officials said at a briefing they treated 18 children, including six who remained in critical condi-

tion and three in serious condition on Monday.

The rest were in fair condition or released. The hospital made no mention of any fatalities. A message posted on Monday by the Milwaukee Dancing Grannies Facebook page paid tribute to those who lost their lives as "the glue ... (that) held us together." "Those who died were extremely passionate Grannies. Their eyes gleamed....[with the] joy of being a Grannie," read the message. "Our hearts are heavy at this most difficult time."

Waukesha schools were closed on Monday, and additional counselors were to be made available for students, the school district superintendent said. Waukesha authorities said a fund for the affected families had been set up.

U.S. President Joe Biden said his administration was monitoring the situation in Waukesha "very closely." "The entire community is struggling, struggling to cope with these horrific acts of violence," Biden told reporters on Monday.

敬請關注我們的新媒體帳號
Follow us on social media



Southern News
美南新聞



美南微信
公眾號



今日頭條
美國美南網



抖音
美國美南網



西瓜视频
美國美南網



Facebook Page
Southern News
美南新聞



Tik Tok ID:
Southern News Group



Instagram ID:
Southern News

China outbound tourism set to jump more than 25% this year - state media

BEIJING, Nov 22 (Reuters) - Chinese outbound tourism numbers are set to jump by more than 25% this year from 2020 but remain “basically at a standstill” compared to pre-pandemic levels, state broadcaster CCTV reported on Monday, citing official projections.

The dramatic drop in travellers from China, the world’s most populous nation, since the rapid spread of coronavirus early last year, has left a \$255 billion annual spending hole in the global tourism market. A total of 25.62 million Chinese tourist trips overseas are expected to be made in 2021, CCTV said, citing an annual report on outbound tourism from the China Tourism Academy, part of the Ministry of Culture and Tourism.

That is up from 20.334 million in 2020, which was itself an 86.9% plunge from a year earlier as the coronavirus outbreak led to severe restrictions on global travel. rojection, which includes trips to special administrative regions of China such as the gambling hub of Macau, will still be well below annual numbers of over 100 million before the pandemic hit, CCTV noted.

Macau, a former Portuguese colony, has become a “bright spot” for out-bound tourism from mainland China due to effective virus prevention and control measures, CCTV said.

The pace of recovery in 2022 will depend on how other destinations handle tourism, it added.

China’s National Immigration Administration said this month it would continue to guide citizens not to go abroad for non-urgent and non-essential reasons. China’s state planner, the National Development and Reform Commission (NDRC), has put out several statements since Tuesday night that it was studying ways to guide prices back to a “reasonable range” and to crack down on “excessive profits” at coal firms. [read more](#)

On Friday, the NDRC said it held a meeting with large state-run companies including oil refiner Sinopec, aluminium giant Chinalco and steelmaker China Baowu on “rational” energy usage by industry on Thursday and said they should take the lead in energy-saving and carbon reduction.



People walk along Nanjing Pedestrian Road, a main shopping area, during the Labour Day holiday, following the outbreak of the coronavirus disease (COVID-19), in Shanghai, China May 5, 2021. REUTERS/Aly Song/File Photo



Editor’s Choice



A woman wearing a burqa sits in the trunk of a taxi in Chawok market in Kabul, Afghanistan. The sticker reads “for God sake stop fighting”. REUTERS/Zohra Bensemra



Fishermen bring in their catch from a lake in front of a power plant of the State Development and Investment Corporation (SDIC) outside Tianjin, China. REUTERS/Thomas Peter



A satellite image in infrared color shows smoke rising as lava flows while the Cumbre Vieja volcano continues to erupt on the Canary Island of La Palma, Spain. Maxar Technologies/via REUTERS



People protest against coronavirus measures as police forces stand guard, near the European Commission in Brussels, Belgium, November 21. REUTERS/Johanna Geron



Migrants wait to disembark from a boat towed by a Spanish coast guard vessel, in the port of Arguineguin, on the island of Gran Canaria, Spain. REUTERS/Borja Suarez



The sky goes orange behind the Washington Monument and the Smithsonian Castle as a couple pose for a sunset selfie in Washington. REUTERS/Kevin Lamarque

BUSINESS

COVID-19 In The U.S. Update

CDC Panel Endorses COVID-19 Vaccine Boosters For All Adults



Compiled And Edited By John T. Robbins, Southern Daily Editor

A key outside advisory group to the Centers for Disease Control and Prevention (CDC) has endorsed the use of COVID-19 booster shots for all adults, a one-size-fits-all approach designed to simplify eligibility. If CDC Director Rochelle Walensky signs off on the broader use, as expected, the extra shots will be available immediately to all adults, as long as they are six months past the final dose of a Pfizer or Moderna vaccine, or two months after a Johnson & Johnson dose. The recommendation from the panel comes just hours after the Food and Drug Administration (FDA) authorized both Pfizer and Moderna’s booster shots for everyone over the age of 18. Pfizer applied to the FDA earlier this month for an expansion of the emergency authorization for its booster shot to make it available to anyone 18 or older. Moderna announced just this week that it too had asked the FDA to allow its booster to be given to all adults. Boosters for everyone has always been the Biden administration’s goal, but until now federal health authorities have stopped short of such a policy, and instead recommended boosters for only specific populations — those over age 65, anyone at high risk because of work or where they live, or those with an underlying medical condition. The primary COVID-19 vaccination continues to provide good protection against severe disease and death, even as effectiveness against milder infection has waned. But cases have been steadily rising across the country, and authorities have said they

want to stave off another winter surge.



The current recommendations, while fairly broad, have caused confusion. While people over the age of 65 are most at risk from waning vaccine immunity, fewer than 40 percent of them have received a booster, according to CDC data. “The current guidelines, though well-intentioned and thoughtful, generate an obstacle to uptake of boosters. In pursuit of precision, they create confusion,” Nirav Shah, president of Association of State and Territorial Health Officials, told the panel. The panel did not make a distinction in their recommendation between the two types of mRNA vaccines, despite the potential for increased risk of myocarditis — a type of heart inflammation — in young men after receiving Moderna’s vaccine. CDC officials told the panel it’s too early to draw conclusions on the risk of myocarditis after the third dose of mRNA vaccines, because teens and younger adults haven’t yet been boosted in large enough numbers. Several other countries have discouraged use of the Moderna vaccine in people

younger than 30 because of that risk. **Gottlieb Says He Expects The CDC Will Consider ‘Fully Vaccinated’ As Including Boosters**



Former Food and Drug Administration Commissioner Scott Gottlieb Former Food and Drug Administration Commissioner Scott Gottlieb said on Sunday that he expects the Centers for Disease Control and Prevention (CDC) to consider Americans “fully vaccinated” when they receive a booster shot, adding that recommendations to change it would likely not happen this year. “Should the CDC say you need a booster to be considered fully vaccinated?” “Face the Nation” moderator Margaret Brennan asked Gottlieb on CBS. “I think at some point they’re going to, but not this year,” Gottlieb answered. “I think eventually this will be considered the three-dose vaccine, but I would be hard pressed to believe CDC is going to make that recommendation any time soon, in part because of this debate about whether or not younger people who are less risk should be receiving that third dose in states where governors are looking to do this, and I think some local communities will do it,” he added. Gottlieb was also asked about CDC saying last week that all American adults could get a booster shot while specifically recommending that people over the age of 50 get their boosters.



“I think the reluctant nature by which CDC has been stepping into this debate reflects a broader ambivalence or a broader debate happening in a public health community about whether the vaccines should be used as tools to protect people from bad outcomes from COVID, or whether they should be used as tools to try to end the pandemic and control transmission,” Gottlieb said. CDC Director Rochelle Walensky late last week signed off on a recommendation from a CDC advisory panel to broaden el-

igibility of the COVID-19 booster to all American adults. The advisory panel had also recommended that those over the age of 50 should get their booster shot.

Fauci Hopes COVID-19 Booster Increases Durability To Not Need It Regularly

President Biden’s chief medical adviser Anthony Fauci said on Sunday that he hopes COVID-19 boosters will increase vaccine durability so that “you will not necessarily need it” every six months or year. “We would hope - and this is something that we’re looking at very carefully - that that third shot with the mRNA not only boosts you way up but increases the durability so that you will not necessarily need it every six months or a year,” Fauci said during “This Week” on ABC.



President Biden’s chief medical adviser Anthony Fauci

“We’re hoping it pushes it out more. If it doesn’t, and the data show we do need it more often, then we’ll do it,” he added. Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky signed off on a CDC advisory panel’s recommendation to increase eligibility for booster shots to all American adults. The decision means that all adults who are at least six months out since receiving their second shot of the Pfizer or Moderna vaccines are now able to get their third shot of the COVID-19 vaccine. “Booster shots have demonstrated the ability to safely increase people’s protection against infection and severe outcomes and are an important public health tool to strengthen our defenses against the virus as we enter the winter holidays. Based on the compelling evidence, all adults over 18 should now have equitable access to a COVID-19 booster dose,” Walensky said in a statement regarding the news. The decision comes only weeks after children as young as 5 years old became eligible to get COVID-19 vaccine, much to the relief of parents and health officials seeking to have their kids inoculated in time for holiday gatherings.



Despite widespread vaccine availability, however, it has not stopped the U.S. from passing the grim milestone last week of recording more COVID-19 deaths in 2021 than last year. (Courtesy thehill.com)

OSHA Suspends Enforcement Of COVID-19 Vaccine Mandate For Businesses

The Occupational Safety and Health Administration (OSHA) is suspending enforcement of the Biden administration’s COVID-19 vaccine mandate for large private businesses after a federal appeals court upheld a stay on it last week.



OSHA said in a statement published on its website Friday night that while it is confident in its power to protect workers amid the pandemic, it is suspending activities related to the mandate, citing the pending litigation. “The court ordered that OSHA ‘take no steps to implement or enforce’ the ETS [Emergency Temporary Standard] ‘until further court order.’ While OSHA remains confident in its authority to protect workers in emergencies, OSHA has suspended activities related to the implementation and enforcement of the ETS pending future developments in the litigation,” OSHA said.



President Biden announced in September that the administration was rolling out a new rule that would require all private employers with 100 or more employees to mandate vaccines or weekly testing for all personnel, a guideline that has the potential to impact nearly 80 million workers. Earlier this month the administration set Jan. 4 as the deadline for qualifying private employers to start mandating the vaccine or requiring weekly testing. The rule was developed by OSHA. In a 22-page ruling last week, the 5th U.S. Circuit Court of Appeals wrote that the administration’s COVID-19 vaccine and testing mandate was “fatally flawed” and ordered that OSHA not enforce the requirement “pending adequate judicial review” of a motion for a permanent injunction. The court said OSHA should “take no steps to implement or enforce the mandate until further court order.” (Courtesy thehill.com)

COMMUNITY

A Daily Pill To Treat COVID-19 Could Be Just Months Away, Scientists Say



Results of trials on a daily pill to treat COVID-19 could be available within in months.(Image/Unsplash/Halacious)


Key Point

- *At least three antivirals for COVID are in clinical trials.*
- *An early trial of 202 participants last Spring showed that molnupiravir rapidly reduced the levels of infectious virus.*
- *Antivirals are already essential treatments for viral infections, including hepatitis C and HIV.*
- *The drugs work by interfering with the virus’s ability to replicate in human cells*

Compiled And Edited By John T. Robbins, Southern Daily Editor

Within a day of testing positive for Covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble breathing, symptoms serious enough to send her to the emergency room. When her husband, Joe, 46, fell ill with the virus, too, she really got worried, especially about their five teenagers at home: “I thought, ‘I hope to God we don’t wind up on ventilators. We have children. Who’s going to raise these kids?’” But the Kellys, who live in Seattle, had agreed just after their diagnoses to join a clinical trial at the nearby Fred Hutch cancer research center that’s part of an international effort to test an antiviral treatment on the unvaccinated that could halt Covid early in its course. By the next day, the couple were taking four pills, twice a day. Though they weren’t told whether they had received an active medication or placebo, within a week, they said, their symptoms were better. Within two weeks, they had recovered. “I don’t know if we got the treatment, but I kind of feel like we did,” Miranda Kelly said. “To have all these underlying conditions, I felt like the recovery was very

quick.” The Kellys have a role in developing what could be the world’s next chance to thwart Covid: a short-term regimen of daily pills that can fight the virus early after diagnosis and conceivably prevent symptoms from developing after exposure.



“Oral antivirals have the potential to not only curtail the duration of one’s Covid-19 syndrome, but also have the potential to limit transmission to people in your household if you are sick,” said Timothy Sheahan, a virologist at the University of North Carolina-Chapel Hill who has helped pioneer these therapies. Antivirals are already essential treatments for other viral infections, including hepatitis C and HIV. One of the best known is Tamiflu, the widely prescribed pill that

can shorten the duration of influenza and reduce the risk of hospitalization if given quickly. The medications, developed to treat and prevent viral infections in people and animals, work differently depending on the type. But they can be engineered to boost the immune system to fight infection, block receptors so viruses can’t enter healthy cells, or lower the amount of active virus in the body.

At least three promising antivirals for Covid are being tested in clinical trials, with results expected as soon as late fall or winter, said Carl Dieffenbach, director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, who is overseeing antiviral development. “I think that we will have answers as to what these pills are capable of within the next several months,” Dieffenbach said. The top contender is a medication from Merck and Ridgeback Biotherapeutics called molnupiravir, Dieffenbach said. This is the product being tested in the Kellys’ Seattle trial. Two others include a candidate from Pfizer, known as PF-07321332, and AT-527, an antiviral produced by Roche and Atea Pharmaceuticals.



They work by interfering with the virus’s ability to replicate in human cells. In the case of molnupiravir, the enzyme that copies the viral genetic material is forced to make so many mistakes that the virus can’t reproduce. That, in turn, reduces the patient’s viral load, shortening infection time and preventing the kind of dangerous immune response that can cause serious illness or death. So far, only one antiviral drug, remdesivir, has been approved to treat Covid. But it is given intravenously to patients ill enough to be hospitalized, and is not intended for early, widespread use. By contrast, the top contenders under study can be packaged as pills. Sheahan, who also performed preclinical work on remdesivir, led an early study in mice that showed that molnupiravir could prevent early disease caused by SARS-CoV-2, the virus that causes Covid. The formula was discovered at Emory University and later acquired by Ridgeback and Merck.

Clinical trials have followed, including an early trial of 202 participants last spring that showed that molnupiravir rapidly reduced the levels of infectious virus. Merck chief executive Robert Davis said this month that the company expects data from its larger phase 3 trials in the coming weeks, with the potential to seek emergency use authorization from the Food and Drug Administration “before year-end.” Pfizer launched a combined phase 2 and 3 trial of its product Sept. 1, and Atea officials said they expect results from phase 2 and phase 3 trials later this year. If the results are positive and emergency use is granted for any product, Dieffenbach said, “distribution could begin quickly.” That would mean millions of Americans soon could have access to a daily orally administered medication, ideally a single pill, that could be taken for five to 10 days at the first confirmation of Covid infection.



“When we get there, that’s the idea,” said Dr. Daniel Griffin, an infectious diseases and immunology expert at Columbia University. “To have this all around the country, so that people get it the same day they get diagnosed.” Once sidelined for lack of interest, oral antivirals to treat coronavirus infections are now a subject of fierce competition and funding. In June, the Biden administration announced it had agreed to obtain about 1.7 million treatment courses of Merck’s molnupiravir, at a cost of \$1.2 billion, if the product receives emergency authorization or full approval. The same month, the administration said it would invest \$3.2 billion in the Antiviral Program for Pandemics, which aims to develop antivirals for the Covid crisis and beyond, Dieffenbach said. The pandemic kick-started a long-neglected effort to develop potent antiviral treatments for coronaviruses, said Sheahan. Though the original SARS virus in 2003 gave scientists a scare—followed by Middle East respiratory syndrome, or MERS, in 2012—research efforts slowed when those outbreaks did not persist. “The commercial drive to develop any products just went down the tubes,” said Sheahan. Widely available antiviral drugs would join the monoclonal antibody therapies

already used to treat and prevent serious illness and hospitalizations caused by Covid. The lab-produced monoclonal antibodies, which mimic the body’s natural response to infection, were easier to develop but must be given primarily through intravenous infusions. The federal government is covering the cost of most monoclonal products at \$2,000 a dose. It’s still too early to know how the price of antivirals might compare. Like the monoclonal antibodies, antiviral pills would be no substitute for vaccination, said Griffin. They would be another tool to fight Covid. “It’s nice to have another option,” he said.



One challenge in developing antiviral drugs quickly has been recruiting enough participants for the clinical trials, each of which needs to enroll many hundreds of people, said Dr. Elizabeth Duke, a Fred Hutch research associate overseeing its molnupiravir trial. Participants must be unvaccinated and enrolled in the trial within five days of a positive Covid test. Any given day, interns make 100 calls to newly Covid-positive people in the Seattle area—and most say no. “Just generally speaking, there’s a lot of mistrust about the scientific process,” Duke said. “And some of the people are saying kind of nasty things to the interns.” If the antiviral pills prove effective, the next challenge will be ramping up a distribution system that can rush them to people as soon as they test positive. Griffin said it will take something akin to the program set up last year by UnitedHealthcare, which sped Tamiflu kits to 200,000 at-risk patients enrolled in the insurer’s Medicare Advantage plans. Merck officials predicted the company could produce more than 10 million courses of therapy by the end of the year. Atea and Pfizer have not released similar estimates. Even more promising? Studies evaluating whether antivirals can prevent infection after exposure. “Think about that,” said Duke, who is also overseeing a prophylactic trial. “You could give it to everyone in a household, or everyone in a school. Then we’re talking about a return to, maybe, normal life.” (Courtesy weforum.org)



讓孩子們把美術作品、 科學功課，以及好成績帶回家， 將COVID-19拒於門外。

將傳染力極強的Delta變種病毒拒於家門外，使之遠離您的家人。因此，讓您的孩子在符合資格時立即接種疫苗極其重要。數據證實疫苗有效對抗Delta變種病毒，並且依然是保護您的孩子和家中每位成員的最佳方法。

如有任何疑問，請向您的醫生查詢。
前往[vaccines.gov](https://www.vaccines.gov)搜尋您附近的疫苗接種點。

抗擊疫情
我們做得到！



以上由美國衛生與公共服務部提供。